Lactoferrin Inhibition of the Complex Formation between ACE2 Receptor and SARS CoV-2 Recognition Binding Domain

The present investigation focuses on the analysis of the interactions among human lactoferrin (LF), SARS-CoV-2 receptor-binding domain (RBD) and human angiotensin-converting enzyme 2 (ACE2) receptor in order to assess possible mutual interactions that could provide a molecular basis of the reported preventative effect of lactoferrin against CoV-2 infection. In particular, kinetic and thermodynamic parameters for the pairwise interactions among the three proteins were measured via two independent techniques, biolayer interferometry and latex nanoparticle-enhanced turbidimetry. The results obtained clearly indicate that LF is able to bind the ACE2 receptor ectodomain with significantly high affinity, whereas no binding to the RBD was observed up to the maximum physiological lactoferrin concentration range. Lactoferrin, above 1 mu M concentration, thus appears to directly interfere with RBD-ACE2 binding, bringing about a measurable, up to 300-fold increase of the K-D value relative to RBD-ACE2 complex formation.

Automated summary

This study investigates the interactions among human lactoferrin, SARS-CoV-2 receptor-binding domain, and human angiotensin-converting enzyme 2 receptor. The results suggest that lactoferrin can bind to ACE2 receptor but not to RBD. This reveals a potential mechanism for lactoferrin's preventive effect against CoV-2 infection by interfering with RBD-ACE2 binding.